NCT03534700

Brief Summary

Chronic sacrococcygeal pilonidal disease is a common acquired condition associated with hirsutism that predominantly affects young male patients. Morbidity from this disease results in pain, embarrassment and loss of normal activities, causing absenteeism from work and school. Various surgical procedures have been described for the treatment of both primary and recurrent pilonidal disease counting: open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap. No single method has been accepted as the "gold standard", and none of them cancels the risk of recurrence. The optimal therapy for pilonidal sinus disease should be simple, with good aesthetic outcomes and a low recurrence rate. It must allow the return to normal activities quickly. The parasacral perforator flap seems to answer these entire requirements. No study compares this flap repair with the most common procedure, which is the open excision with secondary healing. The aim of this study is to assess the efficacy and the security of the reconstruction of the natal cleft with the perforator parasacral flap versus open excision with secondary healing in the treatment of sacrococcygeal pilonidal sinus.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 24, 2017

Completed
6 months until next milestone

First Posted

Study publicly available on registry

May 23, 2018

Completed
9 days until next milestone

Study Start

First participant enrolled

June 1, 2018

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
3.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 25, 2023

Completed
Last Updated

January 3, 2024

Status Verified

January 1, 2024

Enrollment Period

2.3 years

First QC Date

November 24, 2017

Last Update Submit

January 2, 2024

Conditions

Keywords

sacrococcygeal pilonidal disease

Outcome Measures

Primary Outcomes (1)

  • recurrence

    the rate of recurrence during a follow up of 2 years.

    2 years

Secondary Outcomes (2)

  • cost-effectiveness

    2 years

  • cost-utility

    2 years

Study Arms (2)

Open excision

ACTIVE COMPARATOR

open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.

Procedure: open excision

parasacral flap reconstruction

EXPERIMENTAL

The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.

Procedure: parasacral flap reconstruction

Interventions

parasacral flap reconstruction

parasacral flap reconstruction
open excisionPROCEDURE

open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.

Open excision

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with primary or recurrent sacrococcygeal pilonidal sinus disease,
  • Minimum delay of 1 month after an infection of the pilonidal areas,

You may not qualify if:

  • Florid abcess in the pilonidal sinus,
  • Impossibility of general anesthesia, allergy to methylene blue, anticoagulant therapy,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University Hospital

Montpellier, 34295, France

Location

University hospital

Toulouse, 31059, France

Location

Study Officials

  • Benoit CHAPUT, MD

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 24, 2017

First Posted

May 23, 2018

Study Start

June 1, 2018

Primary Completion

September 1, 2020

Study Completion

September 25, 2023

Last Updated

January 3, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations